BioSpace News Archive

Drug Development

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

Companies plan to file for full marketing approval to EMA and FDA in 2020

January 24, 2019
·
8 min read
Policy

Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares

Swedish Orphan Biovitrum AB announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US, as announced on 13 November 2018.

January 24, 2019
·
7 min read
Business

G-Cubed Supplement an Important Health Staple for Upcoming American Heart Month

Product from Infuse Your Life Health Products designed to support cardiovascular health

January 24, 2019
·
1 min read
Business

Farlong’s NotoGinseng Heart Formula Perfect for American Heart Month

American Heart Month in February is a good time to take stock in your health, specifically your heart, and what you should do going forward.

January 24, 2019
·
1 min read
Dr. Reddy’s Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market

Dr. Reddy’s Laboratories Ltd. today announced the launch of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (USFDA).

January 24, 2019
·
3 min read
Business

Bristol-Myers Squibb Reports Fourth Quarter of 2018 and Full Year Financial Results

Increases Fourth Quarter Revenues 10% to $6.0 Billion, 9% for Full Year to $22.6 Billion

January 24, 2019
·
28 min read
Business

Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas

January 24, 2019
·
4 min read
iAnthus Named to 2019 OTCQX Best 50

iAnthus Capital Holdings, Inc. is pleased to announce it has been named to the 2019 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.

January 24, 2019
·
2 min read
Drug Development

Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression

Navitor Pharmaceuticals, the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives, announced today the initiation of Part B of its Phase 1 clinical study with its lead candidate, NV-5138, for treatment-resistant depression (TRD).

January 24, 2019
·
5 min read
Biotech Bay

Tangible Science Introduces Lens Care System for Custom Contact Lenses Coated with Tangible Hydra-PEG

New Products Designed to Ensure Unique Coating Prevents Deposits, Fogging and Patient Discomfort for the Prescribed Life of Lenses

January 24, 2019
·
2 min read